.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Medtronic
Chubb
McKinsey
Farmers Insurance
Queensland Health
Express Scripts
Citi
Federal Trade Commission
Baxter

Generated: January 23, 2018

DrugPatentWatch Database Preview

US Patents With Foreign Priority to Denmark Patent: 0931/96

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novo Nordisk IncSAXENDAliraglutide recombinantSOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes➤ Subscribe➤ SubscribeYY
Novo Nordisk IncVICTOZAliraglutide recombinantSOLUTION;SUBCUTANEOUS022341-001Jan 25, 2010RXYesYes➤ Subscribe➤ SubscribeYY
Novo Nordisk IncXULTOPHY 100/3.6insulin degludec; liraglutideSOLUTION;SUBCUTANEOUS208583-001Nov 21, 2016RXYesYes➤ Subscribe➤ SubscribeY
Novo Nordisk IncSAXENDAliraglutide recombinantSOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes➤ Subscribe➤ SubscribeYYMETHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
Novo Nordisk IncVICTOZAliraglutide recombinantSOLUTION;SUBCUTANEOUS022341-001Jan 25, 2010RXYesYes➤ Subscribe➤ SubscribeYYA METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
Novo Nordisk IncXULTOPHY 100/3.6insulin degludec; liraglutideSOLUTION;SUBCUTANEOUS208583-001Nov 21, 2016RXYesYes➤ Subscribe➤ SubscribeYY
Novo Nordisk IncSAXENDAliraglutide recombinantSOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes➤ Subscribe➤ SubscribeYYMETHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
Novo Nordisk IncVICTOZAliraglutide recombinantSOLUTION;SUBCUTANEOUS022341-001Jan 25, 2010RXYesYes➤ Subscribe➤ SubscribeYYA METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
Novo Nordisk IncXULTOPHY 100/3.6insulin degludec; liraglutideSOLUTION;SUBCUTANEOUS208583-001Nov 21, 2016RXYesYes➤ Subscribe➤ SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist